A Study of Treating Noncytotoxic Drug Extravasation by Compound Sodium Aescinate Gel Combining with Dexamethasone

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000041130

Enrollment

Unknown

Registered

2020-12-19

Start date

2021-01-01

Completion date

Unknown

Last updated

2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extravasation

Interventions

sub-group A1 (Group A):20g CSA Gel only

sub-group A2 (Group A):20g CSA Gel with 5mg DXM

sub-group B1 (Group B):20g CSA Gel with 5mg DXM

sub-group B2 (Group B):20g CSA Gel with 10mg DXM

sub-group C1 (Group C):20g CSA Gel with 10mg DXM

sub-group C2 (Group C):20g CSA Gel with 20mg DXM

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Hospitalized patients with drug extravasation and no ulcer, blister or necrosis on the skin; 2. Patients with extravasation drugs without specific antidote; 3. Patients reported and treated within 1 hour after extravasation; 4. Patients treated with other topical drugs during the study; 5. Patients over 18 years old.

Exclusion criteria

Exclusion criteria: 1. Patients with allergy to Compound Sodium Aescinate Gel and dexamethasone; 2. Pregnant women and lactating women; 3. Subjects with incomplete records due to various reasons.

Design outcomes

Primary

Measure	Time frame
Healing time;	—

Secondary

Measure	Time frame
Decreased pain score (DPS);Decreased edema area (DEA);Normal color skin rate (NCSR);	—

Countries

China

Contacts

Public ContactLiangxiang He

Xiangya Hospital of Central South University

1685770408@qq.com+86 13975886720

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026